CLOV

In the past six months, Clover Health's stock (CLOV) has been impacted by several events, including its Q1 2026 earnings conference call on May 6, 2026, and its Q2 2026 earnings conference call on August 5, 2026. For Q2 2026, the company reported an EPS of $0.05, exceeding analysts' expectations of $0.04. On October 8, 2026, Clover Health announced that its PPO Medicare Advantage plans received a 5-Star rating and its HMO MA plan received a 4.5-Star rating from CMS for 2027, affecting payment year 2028. This significantly improved the percentage of members in plans with four or more stars from 3% in 2026 to 100% in 2027, with the 5-Star PPO rating allowing for year-round beneficiary enrollment. The 5-Star rating for PPO plans was calculated after CMS removed 20 measures due to a court decision, which is under appeal; with these measures, PPO plans would have received 4.5 Stars. Through the first half of 2026, Medicare Advantage membership grew approximately 48% year-over-year to over 157,000 members. There has also been recent market discussion around a potential "Humana Deal Buzz." As of October 8, 2026, the share price was $4.58, an increase from $2.67 on October 9, 2025.